Overview

Escalating Clopidogrel by Involving a Genetic Strategy - Thrombolysis In Myocardial Infarction 56

Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
To determine whether higher as compared with lower maintenance doses of clopidogrel can adequately improve the degree of platelet inhibition in carriers of a reduced-function CYP2C19 allele.
Phase:
Phase 2
Details
Lead Sponsor:
The TIMI Study Group
Collaborators:
Bristol-Myers Squibb
Sanofi
Treatments:
Clopidogrel
Ticlopidine